New Agents on the Horizon

  • Jochen Klupp
  • Randall E. Morris


Today, many new small and large molecular weight molecules are being developed for use as immunosuppressive agents. As the understanding of mechanisms of immune function improves, immunosuppressive drug discovery and development is able to more specifically target activation pathways that predominate in immune rather than nonimmune cells, thus decreasing nonspecific toxicity.


Graft Survival Mycophenolate Mofetil Renal Allograft Delay Graft Function Mixed Lymphocyte Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Terasaki PI, Cecka JM, Gjertson DW, Takemoto S, Cho YW, Yuge J. Risk rate and long-term kidney transplant survival. Los Angeles: UCLA Tissue Typing Laboratory; 1997.Google Scholar
  2. 2.
    Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 1997;73(861):386–390.PubMedCrossRefGoogle Scholar
  3. 3.
    Vella JP, O’Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13(8):2027–2032.PubMedCrossRefGoogle Scholar
  4. 4.
    Novick AC, Ho-Hsieh H, Steinmuller DS, et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: results of randomized prospective trial. Transplantation 1986;42:154.PubMedCrossRefGoogle Scholar
  5. 5.
    Kahan BD. Drug Therapy: Cyclosporine. N Engl J Med 1989;321(25): 1725–1738.PubMedCrossRefGoogle Scholar
  6. 6.
    Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (tl/2). Transplantation 1994;57(6):857–859.PubMedCrossRefGoogle Scholar
  7. 7.
    Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993;55(5):993–995.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhou YC, Cecka JM. Sensitization in renal transplantation. Clin Transpl 1991;1991:313–323.Google Scholar
  9. 9.
    Katznelson S, Cecka JM. Immunosuppressive regimens and their effects on renal allograft outcome. Clin Transpl 1996:361–371.Google Scholar
  10. 10.
    Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995;1995(379):379–394.Google Scholar
  11. 11.
    Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997;64(9): 1277–1282.PubMedCrossRefGoogle Scholar
  12. 12.
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998;65(4): 515–523.PubMedCrossRefGoogle Scholar
  13. 13.
    Tejani A, Sullivan EK. Factors that impact on the outcome of second renal transplants in children. Transplantation 1996;62(5):606–611.PubMedCrossRefGoogle Scholar
  14. 14.
    Gjertson DW. Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry: a 1994 update. Clin Transpl 1994:519–539.Google Scholar
  15. 15.
    Cecka JM. The UNOS Scientific Renal Transplant Registry-ten years of kidney transplants. Clin Transpl 1997:1–14.Google Scholar
  16. 16.
    Thorogood J, Houwelingen JC, Persijn GG, Zantvoort FA, Schreuder GM, van RJ. Prognostic indices to predict survival of first and second renal allografts. Transplantation 1991; 52(5):831–836.PubMedCrossRefGoogle Scholar
  17. 17.
    Zandvoort FA, D’Amaro J, Persijn GG, Cohen B, Schreuder GM, van Rood JJ, et al. The impact of HLA-A matching on long-term survival of renal allografts. Transplantation 1996;61(5):841–844.CrossRefGoogle Scholar
  18. 18.
    Mytilineous J, Lempert M, Middleton D, Williams F, Cullen C, Scherer S, et al. HLA class I of 215 “HLA-A,-B,-DR zero mismatched” kidney transplants. Tissue Antigens 1997;50:355–358.CrossRefGoogle Scholar
  19. 19.
    Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplant. 1985;40:240–243.CrossRefGoogle Scholar
  20. 20.
    Hata Y, Ozawa M, Takemoto S, Cecka JM. HLA Matching. In: Terasaki PI, editor. Clinical Transpl. Los Angeles: UCLA Tissue Typing Laboratory; 1997. p. 381–396.Google Scholar
  21. 21.
    Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333(6):333–336.PubMedCrossRefGoogle Scholar
  22. 22.
    Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995;59(4):565–572.PubMedGoogle Scholar
  23. 23.
    Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997;100(5):1199–1203.PubMedCrossRefGoogle Scholar
  24. 24.
    Tullius SG, Heemann U, Hancock WW, Azuma H, Tilney NL. Long-term kidney isografts develop functional and morphological changes which mimic those of chronic allograft dysfunction. Ann Surg 1994;220:425–432.PubMedCrossRefGoogle Scholar
  25. 25.
    Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995;59(7):962–968.PubMedCrossRefGoogle Scholar
  26. 26.
    Alegre ML, Lenschow DJ, Bluestone JA. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Dig Dis Sci 1995;40(1):58–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Attavar P, Budhai L, Kim BH, Roy-Chowdhury N, Roy-Chowdhury J, Davidson A. Mechanisms of intrathymic tolerance induction to isolated rat hepatocyte allografts. Hepatology 1997;26(5): 1287–1295.PubMedCrossRefGoogle Scholar
  28. 28.
    Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice: Optimal cellular antigen for induction of immunological tolerance with ALS. Tran Proc 1970;2:489.Google Scholar
  29. 29.
    Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995;6(4):1143–1150.PubMedGoogle Scholar
  30. 30.
    Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM. Central role for CD40/CD40L interactions in transplant rejection. Pediatric Nephrology 1998;2(1):6–15.Google Scholar
  31. 31.
    Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94(16):8789–8794.PubMedCrossRefGoogle Scholar
  32. 32.
    Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors [see comments]. Ann Intern Med 1991; 114(11):954–955.PubMedGoogle Scholar
  33. 33.
    Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sacktein R, Saidman S, et al. Combined HLA-matched donor bone marrow and renal transplantation for multiple myeloma with ESRD: induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480.PubMedCrossRefGoogle Scholar
  34. 34.
    Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994;57(7):979–989.PubMedGoogle Scholar
  35. 35.
    Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. LancetLancet 1996;348(9028):643–648.CrossRefGoogle Scholar
  36. 36.
    Tran H, Acharya M, Auchincloss H, Carpenter CB, McKay D, Kirkman R, et al. Cyclosporine sparing effect of daclizumab in renal transplantation. J Am Soc Nephrol 1999;10:749.Google Scholar
  37. 37.
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments]. Transplantation 1999;67(7): 1036–1042.PubMedCrossRefGoogle Scholar
  38. 38.
    Michael HJ, Francos GC, Burke JF, Besarab A, Moritz M, Gillum D, et al. Comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989;48:805.PubMedCrossRefGoogle Scholar
  39. 39.
    Belitsky P, MacDonald AS, Cohen AD, Crocker J, Hirsch D, Jindal K, et al. Comparison of antilymphocyte globulin and continuous iv cyclosporine as induction immunosuppression for cadaver kidney transplants. Transplant Proc 1991;23:999.PubMedGoogle Scholar
  40. 40.
    Gaston RS, Hudson SL, Deierhoi MH, Barber WH, Laskow DA, Julian BA, et al. Improved survival of primary cadaveric renal allografts in blacks compared with quadruple immunosuppression. Transplantation 1992;53:103.PubMedCrossRefGoogle Scholar
  41. 41.
    Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplants 1993;7:345.Google Scholar
  42. 42.
    Katznelson S, Cecka JM. Immunosuppressive regimens and their effect on renal allograft outcome. In: Terasaki PI, editor. Clin Transpl. Los Angeles: UCLA Tissue Typing Lab; 1997. p. 379–394.Google Scholar
  43. 43.
    Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67(7): 1011–1018.PubMedCrossRefGoogle Scholar
  44. 44.
    Rubin RH, Tolkoff RN, Oliver D, Rota TR, Hamilton J, Betts RF, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985;40(3):243–249.PubMedCrossRefGoogle Scholar
  45. 45.
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993;56(1):88–96.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Jochen Klupp
  • Randall E. Morris

There are no affiliations available

Personalised recommendations